2026 ADA | Innovent Presents Multiple Clinical and Preclinical Results of Next-Generation Obesity & Metabolic Pipeline
PR Newswire
SAN FRANCISCO and SUZHOU, China, June 8, 2026
SAN FRANCISCO and SUZHOU, China, June 8, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, presented multiple clinical and preclinical results of its innovative metabolic and obesity pipeline at the 2026 American Diabetes Association's® (ADA) Scientific Sessions. This includes three clinical oral presentations of mazdutide (GCG/GLP-1 dual agonist) across adults with type 2 diabetes and obesity, adults with obesity and adolescents with obesity, as well as preclinical data from its IBI3032 and IBI3042, as next‑generation oral daily and weekly GLP‑1 receptor agonists, along with IBI3040 (a novel amylin analog) and IBI3046 (an INHBE-targeting siRNA). Innovent Biologics' differentiated pipeline aims to provide scientific and comprehensive treatment options for weight management and metabolic comorbidities through offering superior tolerability, reduced muscle loss, convenient dosing, durable efficacy, and integrated comorbidity management.
